- Home
- PAC vs BBIO Comparison
PAC vs BBIO Comparison
Compare PAC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAC | BBIO |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | Mexico | United States |
| Employees | 3637 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 12.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PAC | BBIO |
|---|---|---|
| Price | $248.52 | $67.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 25 |
| Target Price | ★ $270.00 | $86.33 |
| AVG Volume (30 Days) | 69.5K | ★ 2.6M |
| Earning Date | 04-20-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $38.79 | $89.45 |
| Revenue Next Year | $8.96 | $73.78 |
| P/E Ratio | $27.29 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $206.91 | $39.65 |
| 52 Week High | $300.41 | $84.94 |
Technical Indicators
Market Signals| Indicator | PAC | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 49.27 |
| Support Level | $229.49 | $62.39 |
| Resistance Level | $254.72 | $69.78 |
| Average True Range (ATR) | 7.51 | 2.45 |
| MACD | 0.89 | 0.26 |
| Stochastic Oscillator | 92.61 | 72.33 |
Price Performance
Historical ComparisonAbout PAC Grupo Aeroportuario Del Pacifico
Grupo Aeroportuario del Pacifico SAB de CV is engaged in the operation, maintenance, and development of 12 international airports in Mexico and two international airports in Jamaica. The company's segment includes Guadalajara, Tijuana, Puerto Vallarta, San Jose del Cabo, Montego Bay, Hermosillo, and Guanajuato airports. It generates the maximum revenue from the Guadalajara segment.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.